Mara Goldstein
Stock Analyst at Mizuho
(2.52)
# 2,245
Out of 4,886 analysts
77
Total ratings
39.66%
Success rate
4.64%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mara Goldstein
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KURA Kura Oncology | Maintains: Outperform | $32 → $30 | $5.81 | +416.35% | 3 | May 19, 2025 | |
| IOVA Iovance Biotherapeutics | Maintains: Outperform | $30 → $10 | $1.77 | +464.97% | 5 | May 12, 2025 | |
| VSTM Verastem | Maintains: Outperform | $9 → $8 | $4.71 | +69.85% | 7 | Apr 9, 2025 | |
| RCUS Arcus Biosciences | Maintains: Buy | $51 → $42 | $8.50 | +394.12% | 4 | Jan 30, 2024 | |
| XNCR Xencor | Maintains: Buy | $59 → $50 | $8.27 | +504.59% | 2 | Jan 22, 2024 | |
| SNDX Syndax Pharmaceuticals | Initiates: Buy | $45 | $8.75 | +414.29% | 1 | Dec 22, 2023 | |
| INCY Incyte | Maintains: Neutral | $82 → $77 | $67.67 | +13.79% | 5 | Dec 14, 2023 | |
| ERAS Erasca | Maintains: Buy | $8 → $7 | $1.47 | +377.82% | 3 | Nov 29, 2023 | |
| FATE Fate Therapeutics | Maintains: Buy | $12 → $8 | $1.09 | +633.94% | 5 | Nov 20, 2023 | |
| LPTX Leap Therapeutics | Maintains: Buy | $20 → $12 | $0.32 | +3,675.96% | 5 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $90 | $22.73 | +295.95% | 3 | Aug 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $3.5 | $3.96 | -11.62% | 5 | Jun 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $360 | $2.20 | +16,263.64% | 2 | Apr 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $10 → $20 | $4.00 | +400.00% | 2 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $130 | $81.37 | +59.76% | 2 | Apr 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 → $2 | $2.40 | -16.67% | 6 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $12 | $2.36 | +408.47% | 3 | Mar 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $9 | $0.25 | +3,457.31% | 3 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $14 → $20 | $34.25 | -41.61% | 3 | Sep 6, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $34 → $48 | $7.36 | +552.17% | 5 | Jul 8, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $21.33 | - | 2 | Apr 17, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $14 | $4.48 | +212.50% | 1 | Oct 12, 2017 |
Kura Oncology
May 19, 2025
Maintains: Outperform
Price Target: $32 → $30
Current: $5.81
Upside: +416.35%
Iovance Biotherapeutics
May 12, 2025
Maintains: Outperform
Price Target: $30 → $10
Current: $1.77
Upside: +464.97%
Verastem
Apr 9, 2025
Maintains: Outperform
Price Target: $9 → $8
Current: $4.71
Upside: +69.85%
Arcus Biosciences
Jan 30, 2024
Maintains: Buy
Price Target: $51 → $42
Current: $8.50
Upside: +394.12%
Xencor
Jan 22, 2024
Maintains: Buy
Price Target: $59 → $50
Current: $8.27
Upside: +504.59%
Syndax Pharmaceuticals
Dec 22, 2023
Initiates: Buy
Price Target: $45
Current: $8.75
Upside: +414.29%
Incyte
Dec 14, 2023
Maintains: Neutral
Price Target: $82 → $77
Current: $67.67
Upside: +13.79%
Erasca
Nov 29, 2023
Maintains: Buy
Price Target: $8 → $7
Current: $1.47
Upside: +377.82%
Fate Therapeutics
Nov 20, 2023
Maintains: Buy
Price Target: $12 → $8
Current: $1.09
Upside: +633.94%
Leap Therapeutics
Nov 20, 2023
Maintains: Buy
Price Target: $20 → $12
Current: $0.32
Upside: +3,675.96%
Aug 7, 2023
Reiterates: Neutral
Price Target: $90
Current: $22.73
Upside: +295.95%
Jun 16, 2023
Reiterates: Neutral
Price Target: $3.5
Current: $3.96
Upside: -11.62%
Apr 24, 2023
Reiterates: Buy
Price Target: $360
Current: $2.20
Upside: +16,263.64%
Apr 19, 2023
Upgrades: Buy
Price Target: $10 → $20
Current: $4.00
Upside: +400.00%
Apr 10, 2023
Reiterates: Buy
Price Target: $130
Current: $81.37
Upside: +59.76%
Mar 28, 2023
Maintains: Neutral
Price Target: $4 → $2
Current: $2.40
Upside: -16.67%
Mar 8, 2023
Maintains: Buy
Price Target: $18 → $12
Current: $2.36
Upside: +408.47%
Nov 9, 2022
Upgrades: Buy
Price Target: $9
Current: $0.25
Upside: +3,457.31%
Sep 6, 2019
Reiterates: Overweight
Price Target: $14 → $20
Current: $34.25
Upside: -41.61%
Jul 8, 2019
Downgrades: Neutral
Price Target: $34 → $48
Current: $7.36
Upside: +552.17%
Apr 17, 2018
Downgrades: Neutral
Price Target: n/a
Current: $21.33
Upside: -
Oct 12, 2017
Maintains: Overweight
Price Target: $12 → $14
Current: $4.48
Upside: +212.50%